Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZVRA
Strong BuyFull HouseFLAGZevra Therapeutics, Inc. · Healthcare · United States · $687M · Avg Vol: $12M/d
Zevra Therapeutics has strong quality at Q84 but value at V41 is below the calibrated floor, so stage one fails. Insider selling of 0.06% is separately adverse.
COMPANY DESCRIPTION
Zevra Therapeutics, Inc. is a rare disease therapeutics company dedicated to developing and commercializing novel treatments for patients with unmet medical needs, particularly focusing on neurological and endocrine disorders. The company strategically targets highly specialized, underserved patient populations, leveraging orphan drug designations to create a competitive advantage. Zevra is focused on advancing late-stage clinical candidates and commercializing treatments that address significant gaps in care for rare diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.2M | 27.5M | 23.6M | 106.5M | 118.8% | 136.1M | 152.2M | 177.0M | 28.9% |
| EPS | -1.20 | -1.30 | -2.28 | 1.35 | — | 0.93 | 1.14 | 1.05 | -11.8% |
| Shares | 34.5M | 41.5M | 53.7M | 56.9M | +64.6% | 59.4M | — | — | — |
| Debt | 14.1M | 43.8M | 60.3M | 63.2M | 64.8% | — | — | — | — |
| Equity | 75.1M | 61.9M | 39.7M | 154.7M | 27.2% | — | — | — | — |
| Op CF | -18.7M | -33.5M | -69.7M | -1.6M | — | 33.4M | — | — | — |
| Inv CF | -36.7M | -17.4M | -22.2M | 18.1M | — | — | — | — | — |
| Fin CF | 8.4M | 28.5M | 82.1M | 12.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZVRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZVRA | Zevra Therapeutics, Inc.(you) | $687M | 91 | Strong Buy |
| CRMD | CorMedix Inc. | $647M | 98 | Strong Buy |
| QTTB | Q32 Bio Inc. | $447M | 89 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $868M | 99 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $468M | 98 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $310M | 93 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| MDXG | MiMedx Group, Inc. | $656M | 73 | Buy |
| TBPH | Theravance Biopharma, Inc. | $885M | 76 | Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%